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Cutaneous T-cell lymphoma is typically a clonal neoplasm ofepidermotropic CD4+ T-lymphocytes
that includes the entity mycosisfungoides (MF). After identification ofpatients with recurrent MF
treated with total skin electron beam therapy (TSEBT) at the Yale University School ofMedicine,
this study attempted to compare T-cell receptor (TCR) ygene rearrangements viapolymerase chain
reaction (PCR) in both original and recurrent skin biopsiesfrom thesepatients. Between 1974 and
1996, a total of95 T2 MFpatients were treated with TSEB, andfour ofthese were identifiedfor the
study. Slides and tissue samples ofboth primary and recurrent skin biopsiesfor each patient were
confirmed as being consistent with MF DNAfor PCR was isolatedfrom paraffin-embedded tissue
samples. Using consensus primers that hybridize with conserved regions of the TCR gene, these
regions ofthe genome wereamplified. ThePCRproducts were then analyzedbyacrylamidegelelec-
trophoresis. Ofthe primary and recurrent samplesfromfour patients with a median disease-free
interval (DFI) of1222 days, only two showed evidence ofa dominant TCR clone. A number offac-
tors, including lackofsequence homology between theprimers andthe gene segments, the existence
ofmultiple neoplastic cell lines, DNA degradation in the archivalsamples, andthepresence ofreac-
tive as well as malignant lymphocytes, may have prevented the detection of dominant TCR
rearranged clones in the samples. Despite the results ofthis study, TCR analysis via PCR and gel
electrophoresis continues to be ofutility in the evaluation ofpatients with MF when used in con-
junction with other diagnostic modalities and in cases with nonspecific clinical, histopathological,
and immunophenotypingfindings.
INTRODUCTION
Cutaneous T-cell lymphoma (CTCL)e
is most commonly a clonal malignancy of
epidermotropic T-lymphocytes, usually of
the CD4+ phenotype, which presents with
a spectrum of clinical manifestations
including mycosis fungoides (MF) and the
Sezary syndrome [1]. CTCL also encom-
passes the less common clinical entities
such as pagetoid reticulosis (Woringer-
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Kollop disease), suppressor (CD8+) T-cell
lymphoma, granulomatous slack skin,
peripheral T-cell lymphoma, adult T-cell
leukemia/lymphoma, CD30+ large cell
lymphoma, and lymphomatoid granulo-
matosis [2]. Evidence from immunophe-
notyping and T-cell receptor gene
rearrangement studies supports the classi-
fication of these dermatoses as forms of
CTCL [3].
A relatively rare disease, CTCL has
an incidence rate of four per 1,000,000.
However, the incidence appears to have
increased by a factor of at least 3.2
between the years 1973 and 1984 [4]. Sev-
eral registries indicate that African-Amer-
icans have the highest incidence ofCTCL,
almost twice that ofwhites. Males are also
twice as likely to be affected as females.
Although risk increases with age, with
most cases being diagnosed during the
fifth and sixth decades of life, one-eighth
of all cases are diagnosed in patients
below the age of 40, with documented
cases in childhood [5, 6]. Approximately
1,000 new cases of CTCL are diagnosed
annually in the United States [2]. A recent
population-based analysis of nine cancer
registries also shows that median survival
forMFpatients in the study was 9.7 years,
with five- and ten-year survival rates of66
percent and 49 percent, respectively [7].
No clear etiology for CTCL has been
identified. Early investigations postulated
that chronic antigenic stimulation of lym-
phocytes in the form of exposure to envi-
ronmental agents such as industrial chem-
icals, metals, pesticides, and tobacco pre-
disposed to the development of CTCL by
promoting the malignant transformation
of affected lymphocytes [8]. These theo-
ries, however, have not been supported by
recent case-control studies [9, 10]. The
possibility of a retroviral etiology also has
been considered, due to the association
between human lymphotropic virus type-I
(HTLV-1) and T-cell leukemias. Although
most patients with CTCL have negative
serologies for HTLV-1, viral particles
have been isolated from the peripheral
blood of some CTCL patients; thus, the
role of HTLV-1 in CTCL is still uncertain
[11]. An association between CTCL and
Epstein-Barr virus has also been reported
[12]. Additionally, mutations of the tal-1
and NFKB2/lyt-10 encoded transcription
factors have been found in a subset of
patients with aggressive disease [3].
The pathological features of CTCL
typically correspond to the developmental
stage of the lesions. Biopsies from the
early stages ofdisease often show nonspe-
cific changes. The early features include
the presence ofa sparse lymphocytic infil-
trate in the papillary dermis with occa-
sional intraepidermal lymphocytes. With
disease progression, lymphocyte atypia
becomes evident, and the infiltrate also
tends to include other cell types such as
eosinophils and plasma cells. Epider-
motropism, or the colonization of the epi-
dermis by cerebriform T-lymphocytes,
clusters of which are known as Pautrier's
microabscesses, are also seen with disease
progression [8]. The predominant cell type
in CTCL is the CD4+ helperT-cell, which
expresses cutaneous lymphoid antigen
(CLA), a P-selectin cell surface glycopro-
tein that binds to E-selectin on endothelial
cells in the skin [12]. CLA as well as inter-
feron elaborated by both neoplastic and
normal T-cells facilitate the epidermotro-
pism of the tumor cells. With further dis-
ease progression, epidermotropism is
often lost, and tumor nodules involving
the dermis and subdermal structures are
observed.
Differentiating CTCL from a benign
inflammatory reaction may be difficult.
Phenotypically, both may show loss of
CD7 and Leu-8 markers while retaining
CD3 and CD4 positivity [8]. However, the
expression of activation and proliferation
antigens (CD25, CD30, HLA-DR or Ki-
67) and the loss ofpan T-cell antigens sug-
gest neoplastic progression. MonoclonalityThayu et al.: T-cell gene rearrangement in CTCL 367
can be demonstrated by T-cell receptor
gene rearrangement analysis, a process
whereby DNA from biopsy specimens is
extracted, digested with restriction
enzymes, amplified by the polymerase
chain reaction, and fractionated on an
agarose gel [13, 14]. These techniques have
proven to be extremely useful in supporting
a diagnosis of CTCL in very early stages
when histological changes are often non-
specific [15, 16]. The identification of a T-
cellrearrangement signifies the existence of
dominant clone, though not necessarily a
malignant one. Clonality alone is not suffi-
cient for the diagnosis of malignancy; cer-
tain conditions such as Waldenstrom's
macroglobulinemia may be caused by a
monoclonal lymphocyte population.
Hence, evidence from T-cell receptor gene
rearrangement studies must be interpreted
within the larger context of clinical and
pathological findings [8].
The most widely used staging system
for CTCL emphasizes the tumor-node-
metastasis (TNM) classification (Table 1)
[17]. Essentially, the first three phases of
disease correspond to TI or T2 disease,
while the tumorphase is T3. Erythroderma
is always considered T4 disease. Table 2
shows the stage groupings ofMF based on
TNM status [17].
The treatment of MF includes a vari-
ety ofmodalities [18-27]. An evaluation of
tumor burden, atypia, and immunocompe-
tence is essential before the initiation of
therapy, which consists ofthree broad cat-
egories: skin-directed therapy, biological
response modifiers, and chemotherapy
Table 1.TNM classification of CTCLa
T: Skinb
TO Clinically and/or histopathologically suspicious lesions
Ti Limited plaques, papules, or eczematous patches covering <10 percent of
the skin surface
T2 Generalized plaques, papules, or erythematous patches covering >10 percent of
the skin surface
T3 Tumors
T4 Generalized erythroderma
N: Lymph nodesc
NO No clinically abnormal peripheral lymph nodes, pathology negative for CTCL
Ni Clinically abnormal peripheral lymph nodes, pathology negative for CTCL
N2 No clinically abnormal peripheral lymph nodes, pathology positive for CTCL
N3 Clinically abnormal peripheral lymph nodes, pathology positive for CTCL
M: Visceral organs
MO No visceral organ involvement
Mi Visceral involvement (must have pathology confirmation and organ involved
should be specified)
aThe complete classification contains a category in which the number of circulating atypi-
cal cells are noted.This category, however, has never been used forthe clinical staging and
is, therefore, not included here. It has been demonstrated that it is a useful parameter in
this classification except in T4 disease [16].
b Pathology of Ti -4 is diagnostic of CTCL. When more than one T stage exists, both are
recorded, and the highest is used for staging (e.g., T4) [3].
c Record number of sites of abnormal nodes (e.g., cervical [left and right], etc.).368 Thayu etal.: T-cell gene rearrangement in CTCL
Table 2.TNM staging of mycosis fungoides.
Stage T N M
IA Ti NO MO
IB T2 NO MO
IIA T1-2 Ni MO
IIB T3 NO-1 MO
III T4 NO-1 MO
IVA Ti-4 NO-2 Mi
[28]. Skin-directed therapies are most
effective in early disease and are the first
line treatment for T1-T3 stage disease.
They include steroids, topical nitrogen
mustard (mechlorethamine), carmustine
(BCNU), retinoids, phototherapy with
ultraviolet A light (PUVA), and radiother-
apy, which includes both x-ray and elec-
tron beam therapy. Skin-directed therapy
may be used alone or concurrently with
other therapies. Biological response modi-
fiers target abnormal T-cell function and
altered cytokine profiles observed in MF.
Extracorporeal photochemotherapy is
presently employed forT4 disease, and tri-
als with other agents such as retinoids,
cytokines, immunotoxins, and vaccines
are under way [28]. Since biological
response agents are typically used for
refractory or advanced disease, they are
often administered in conjunction with
skin-directed therapies. Chemotherapeutic
agents used in MF include methotrexate,
and T-cell specific agents such as adeno-
sine deaminase inhibitors also have been
used in advanced disease [28, 29].
Recent studies by Wilson et. al., have
identified a subset of T2 MF patients who
fail after 2.5 or more years following total
skin electron beam therapy [25, 30]. It was
postulated that these patients who present
with "late failures" are actually suffering
from second primary tumors rather than
true recurrences, which are usually seen in
the patients who fail within two years of
initial treatment. Using the database of
patients treated atYale-New Haven Hospi-
tal for patch/plaque MF, our study
attempts to evaluate whether or not these
"late failures" actually represent the per-
sistence of original neoplastic clones or
the emergence of second primary neoplas-
tic T-cell clones. By isolating DNA from
original and recurrent tumor biopsy speci-
mens and amplifying the T-cell receptor
variable regions by PCR, the clonality of
the original and recurrent tumors was
compared. Ideally, this information will
impact upon the clinical management of
these patients. Ifthe late failures represent
true recurrences, then further research
upon more aggressive adjuvant and main-
tenance therapy would be warranted. Ifthe
failures proved tobe secondprimaries, this
information would indicate the need to
develop modalities to detect them at earli-
er stages when they are more likely to be
amenable to a complete clinical response.
METHODS
Patientpopulation
Between 1974 and 1996, a total of95
T2 MF patients were evaluated and treated
at theYale University School ofMedicine.
Of these 95 patients, eight were noted to
have recurrences 2.5 or more years after
the completion oftotal skin electron beam
therapy (TSEBT). Four of these patients
were excluded from the study due to either
(1) the unavailability of biopsy materialThayu et al.: T-cell gene rearrangement in CTCL 369
from the time of diagnosis or recurrence
or (2) the fact they may have received
radiation therapy from an outside institu-
tion prior to initial treatment with electron
beam therapy.
All patients were evaluated by mem-
bers oftheYale University School ofMed-
icine Departments of Dermatology and
Therapeutic Radiology. A complete histo-
ry and physical examination of the skin
and lymph node sites were done prior to
the initiation of therapy for each patient.
Three ofthe four patients also had abdom-
inal computed tomography and liver
spleen scans. None ofthe four cases exhib-
ited visceral involvement. All of the
patients in the study were Caucasian; the
median age at diagnosis was 55.8 years,
and there was an equal gender distribution
in the patient population.
Clinical staging
All patients were staged according to
the guidelines of the TNM system for
CTCL [17]. None ofthepatients hadnodal
nor visceral involvement.
Pathology
Both original and relapse histopathol-
ogy specimens from each patient were
reviewed by members of the Yale Univer-
sity Department of Pathology or the Sec-
tion of Dermatopathology prior to the ini-
tiation of therapy. These specimens were
re-examined and the diagnosis confirmed
before the gene rearrangement studies
were performed. Specimens that exhibited
colonization of the epidenrnis with a lym-
phocytic infiltrate with atypical nuclei and
a superficial band-like lymphoid infiltrate
were considered diagnostic of MF. Speci-
mens that exhibited two ofthese three cri-
teria (epidermotropism, atypical nuclei, or
band-like lymphoid infiltrate) were con-
sidered to be consistent with MF.All ofthe
samples in the study were either diagnos-
tic of or consistent with MF.
Therapyprior to TSEBT
Only one of the patients had received
therapy, consisting of topical steroids,
prior to the initiation of TSEBT. Prior
treatment did not influence the TSEBT
protocol.
TSEBTprotocol
Each of the patients in the study were
treated with TSEBT delivered by a 6 mEV
linear accelerator at a distance of7 meters
to a total dose of 36 Gy over a nine to 12
week period. Patients received treatment
to si& fields with orthovoltage boosts to the
perineum (120 kvp, 1 Gy x 20), soles of
feet (120 kvp, 1 Gy x 20), and apical scalp
(120 kvp, 2 Gy x 3). External and internal
eye shields were used throughout therapy,
and the hands and feet were shielded for
50 percent of the course. Therapy was
administered and supervised by a member
ofthe Department ofTherapeutic Radiolo-
gy (LW, BK). The most common sequelae
of therapy included erythema, pruritis,
lower extremity edema, and alopecia.
Assessment ofresponse
Patients were seen in follow-up four
to eight weeks after the completion of
electron beam therapy. They were scored
as having either a complete clinical
response (CCR) or a partial response
based upon the presence of cutaneous
lesions. Each of the four patients in the
study had a complete clinical response to
therapy by eight weeks after the comple-
tion ofTSEBT.
Adjuvant therapy
Adjuvant therapy was defined as treat-
ment administered to patients after a CCR.
Two ofthe four patients had adjuvant ther-
apy consisting of six cycles of cyclophos-
phamide with intravenous doxorubicin on
day one of therapy [31]. One patient
received PUVA therapy, consisting of the
oral administration of 8-methoxypsoralen
followed by the exposure ofthe cutaneous370 Thayu et al.: T-cell gene rearrangement in CTCL
Table 3. PCR cycling conditions forT-cell receptor gene rearrangement study.
Temperature Time No. of cycles
98.40C 10 minutes 1
940C 0.5 minutes 34
550C 0.75 minutes
720C 0.75 minutes
720C 10 minutes 1
300C 1 minute 1
surface to UVA light (320-400 nm) [23,
32, 33]. Treatments were initially two to
four times weekly and then tapered to once
monthly with the maintenance of a CCR.
One patient received adjuvant extracorpo-
real photopheresis as described by Edelson
et. al., in which the patient received 8-
methoxypsoralen followed by the removal
ofblood, pheresis ofleukocytes, treatment
ofleukocytes with ultraviolet light at 25 C,
and reinfusion [34]. The interval between
ECP treatments was extended as the
patient maintained a CCR for greater than
six months.
DNA extraction and T-cell receptor
gene rearrangement studies
After histopathological confirmation
of a diagnosis of MF, DNA was isolated
from each of the paraffin-embedded sam-
ples using the procedure and reagents of
the Easy DNA Kit for Genomic DNA Iso-
lation from InvitrogenTM. After microdis-
section, the tissue samples were washed
with xylene, hydrated, and then rinsed
again with ethanol. The tissue was then
pelleted by microcentrifugation, dried
overnight, and resuspended in TE buffer
with pH 8.0. The quality and quantity of
extracted DNA were assessed by spec-
trophotometry and gel electrophoresis.
Consensus primers that hybridize with
conserved sequences in most of the vari-
able and joining regions of the germline
genome allow for the determination of
clonality. Numerous studies have identi-
fied the optimal conditions and the specif-
ic primer sequences for this assay. Specif-
ically, the following T-cell receptor
primers were used: (1) Beta Chain - Con-
sensus J region 5'AGCAC(GCT)GTG
AGCC(GT)GGTG CC3' Consensus D
region 5'CAAAGCTGTAACATTGTG
GGGACY (2) Gamma chain - Consensus
J region - 5'CGTCGACAACAAGTG
TTGTTCCAC3' Consensus V region -
5'AGGGTGTGTTGGAATCAGG3' [13,
35]. The presence of amplifiable DNA in
the reactions was confirmed by simultane-
ous amplification ofa segment ofthe beta-
globin gene or the HLA gene. The PCR
reactions are performed in 30 p1 aliquots
with 300 ng ofsample DNA in 3 ,ul and 27
g1 of reaction mix, which is composed of
0.12 pl of Amplitaq polymerase-gold
(Perkin-Elmer) and 26.88 pl of reaction
mix. The PCR cycling conditions are list-
ed in Table 3. Two gl of each of the PCR
products from the P-globin, immunoglob-
ulin heavy chain, and T-cell receptor 3
chain reactions were mixed with 4 ,l of
the loading dye solution and then loaded
into the wells of the gel. One pl of the
PCR product of T-cell receptor gamma
chain reaction was first denatured in 3 p1
of stop solution composed of 950 pl for-
mamide, 2 pl 5M NaOH, 25 pl 1 percent
Bromophenol blue, 25 pl 1 percent xyleneThayu et al.: T-cell gene rearrangement in CTCL 371
cyanole. Electrophoresis was performed
using a 15 percent acrylamide gel for 75
minutes at 220v. Appropriate molecular
weight markers were run in one lane in
every gel (AT Biochem Biomarkers EXT
Plus). The gels were bathed in distilled
water and ethidium bromide
(1O,ug/ml/1OOml H20) for three minutes.
Afterwards, the gels were viewed on an
UV light table and recorded using a digital
imager system from Alpha Innitech Cor-
poration [13].
RESULTS
Clinical results
Disease-free survival (DFS) was cal-
culated from the end of TSEBT until the
time of relapse, which, for each of the
patients in the study, was biopsy-docu-
mented after examination by the radiation
oncologist orthe dermatologist. As Table 4
indicates, the median follow-up from the
completion of TSEBT for the patients in
the study was 3593 days, with a median
disease-free interval from the completion
of TSEBT was 1222 days. After relapse,
two patients received PUVA therapy, one
received an additional course of TSEBT,
and one received ECP and limited electron
beam therapy. Three of the four patients
achieved a second CR, while one achieved
a partial response. During the course of
follow-up, one patient was noted to have a
basal cell carcinoma and a squamous cell
carcinoma. Another developed a
melanoma in situ and a basal cell carcino-
ma. At the time of analysis, the patients
had an overall survival of 100 percent.
TCR gene rearrangement study
results
The results of the TCR gamma gene
rearrangements for both original and
recurrent biopsy specimens along with
DNA markers are shown (Figure 1). This
technique allows for the identification of
dominant clones of malignant cells by the
presence of distinct bands upon the gel.
The presence ofa broad smear ofbands as
opposed to distinct bands indicates the
presence ofmultiple clones. PCRproducts
from original and recurrent biopsy speci-
mens for each patient were run adjacent to
each other for comparison of TCR gene
rearrangements. Multiple lanes for either
original or recurrent biopsies indicate
multiple biopsy sites. PCR products in all
lanes except for 6 and 7 show a broad
smear of multiple bands, indicating the
presence ofmultiple clones. Lane 6 repre-
sents the recurrent biopsy for Patient 2,
and lane 7 represents the original biopsy
of Patient 3. Both of these lanes show a
range of polyclonal bands as well as a
range of more distinct dominant clonal
bands. Thus, the presence of dominant
rearranged clones of the TCR gamma
chain is only observed in lanes 6 and 7.
Both original and recurrent biopsies for
patients 1 and 4, the original biopsy for
patient 2, and the recurrent biopsy for
patient 4 do not exhibit the presence of
Table 4. Patient profile.
Patient Age at DFI F/U
No. Race Diagnosis Stage Sex (days) (days)
1 Caucasian 51 T2NOMO M 1310 3204
2 Caucasian 70 T2NOMO F 1419 2173
3 Caucasian 69 T2NOMO F 1027 4134
4 Caucasian 33 T2NOMO M 1130 4859372 Thayu etal.: T-cell gene rearrangement in CTCL
dominant clones of malignant cells. The
presence of the reannealed bands identi-
fied by the asterisks also indicate the pres-
ence of dominant clones in lanes 6 and 7.
DISCUSSION
Molecular analysis of CTCL, specifi-
cally MF, has been extremely valuable in
its diagnosis, particularly in its ability to
distinguish MFfrombenign lymphoprolif-
erative processes, particularly in the early
stages of disease when histopathological
findings can be nonspecific. Immunophe-
notyping, essential to the identification of
T-cell lymphomas, may pose problems in
the diagnosis of cases with an absence of
cell surface markers such as certain imma-
ture T-cell lymphomas and in neoplastic
infiltrates, which also include significant
populations of benign T-cells with pheno-
typic features of malignant cells. Evalua-
tion of TCR gene rearrangements and the
identification of dominant T-cell clonal
populations from biopsy specimens using
Southern blot analysis have been well doc-
umented [36, 37]. The limitations of this
technique include the fact that it is very
labor intensive, time-consuming, and
requires 105 to 106 cells for a single analy-
sis, a quantity not always available from
biopsy specimens [15].
The rationale for evaluating T-cell
receptor gene rearrangements in patients
with MF rests upon the principle that
germline T-lymphocytes undergo
rearrangement of their antigen receptor
genes, which are composed of variable
[VI, diversity [DI,joining [J], and constant
[C] segments, which allows for the great
diversity ofT-cell receptors. MF is typical-
lycharacterizedby aclonalproliferation of
T-cells, indicating that the malignant cells
have identical TCR gene rearrangements.
Although the process of V, D, and J seg-
ment recombination involves the deletion
and insertion ofcertain sequences, particu-
larly at the junctions between segments,
Figure 1.T-cell receptor gamma gene rearrangements ofT2 CTCL patients. Identifi-
cation of lanes.
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portions of the TCR are highly conserved
as well. By using primers for these highly
conserved regions of the rearranged seg-
ments, PCR allows for the amplification of
thisportionoftheTCRgene.A clonalpop-
ulation ofcells should result in DNA frag-
ments that are identical in size, which will
appear as distinct bands after gel elec-
trophoresis [38]. A polyclonal population
will have multiple TCR gene rearrange-
ments, and, therefore, when the PCR prod-
ucts are run on a polyacrylamide gel, a
smear of bands representing DNA frag-
ments of different sizes will appear. This
method of evaluation of TCR gene
rearrangements has its downfalls as well.
Ideally, the presence of a dominant
clone should have been observed in each
of the PCR products. A number of factors
may have contributed to the fact that all of
the lanes other than 6 and 7 demonstrated
polyclonal products. The consensus
primers designed for this assay have a sen-
sitivity of approximately 90 percent [13].
Thus, there is a small possibility that the
assay was not able to detect the TCR
rearrangement in selected samples. This
lack of sequence homology between the
consensus primers and the conserved por-
tions ofthe TCR gene could be due to the
selection of unanticipated V segments or
mutation in response to antigen stimula-
tion [35]. Another factor contributing to
the presence ofmultiple clones is the exis-
tence ofmore than one neoplastic cell line.
Although the likelihood ofthis is rare, this
phenomenon has been documented. Addi-
tionally the presence of multiple clones
could indicate a high-grade neoplasm. In
the case of patient No. 3, whose original
biopsy demonstrates monoclonality and
recurrent biopsy does not, the possibility
of transformation as a result of treatment
must also be considered. The most likely
explanation for the inability to demon-
strate monoclonality in the PCR products,
however, rests on the quality and age of
the samples themselves. Seventy-five per-
cent ofthe original biopsy specimens were
greater than 10 years old at the time of
analysis. Problems associated with diffi-
culty amplifying archival biopsy material
greater than five years old due to DNA
degradation has been documented [16].
Furthermore, the presence ofreactive lym-
phocytes, which are far greater in number
than the clonal malignant cells, may have
prevented the detection of a single neo-
plastic cell line [39].
If the TCR analysis had indeed been
able to establish a dominant clone in each
of the samples, a number of conclusions
potentially could have been drawn from
the data. If, for example, both original and
recurrent biopsy samples had resulted in
PCR products with identical dominant
clones, the analysis would have estab-
lished that the later tumors represented
true recurrences, indicating the persistence
of the original neoplastic clone. Although
the sample size of the studyis quite small
due to the stringent inclusion criteria, this
information would have supported the
need to utilize more effective adjuvant and
maintenance therapies in this subset of
patients. Additionally, any significant dif-
ferences observed between patients who
had received different adjuvant therapies
would have supported the greater efficacy
of one treatment. For example, if both
patients receiving adjuvant chemotherapy
had shown the emergence oftheir original
clones while the twopatients who received
PUVA and ECP had different clones for
their later biopsies, this information could
indicate the greater utility of ECP and
PUVA as adjuvant therapies for this
patient population. Finally, if each of the
patients had shown the emergence of a
new primary neoplastic clone in his or her
recurrent biopsies, this information would
have indicated that the therapy received
was adequate and could be repeated. More
effective surveillance to detect these
lesions at early stages when they are most
amenable to treatment would also be use-374 Thayu etal.: T-cell gene rearrangement in CTCL
ful for this patient population.
Despite the results of this study, TCR
analysis via PCR and gel electrophoresis
continues to be of utility in the evaluation
of patients with MF when used in con-
junction with other diagnostic methods.
Given the ambiguity ofthe clinical presen-
tation of this disease and the difficulty
associated with making a definitive diag-
nosis, the use of this diagnostic modality.
may be ofparticular use in cases with non-
specific clinical, histopathological, and
immunophenotyping findings. In this sub-
set ofpatients who may present with clin-
ical features ofMFbut with no histopatho-
logical nor molecular evidence of disease,
TCR gene rearrangement studies via PCR
could identify those patients who will need
more stringent surveillance and follow-up,
since they may be harboring occult neo-
plasms. Furthermore, in patients with
biopsy documentation of recurrent MF,
this diagnostic tool, given its cost and
indeterminate impact upon therapy, should
not be routinely used.
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